HRonBC: a web-tool tailored for analysis of transcriptomics and nucleome data for Hormone Replacement on Breast Cancer

Vural Özdeniz , Merve
Acar, Rana
Çalışır , Kübra
Leka , Ronaldo
Özden Yılmaz , Gülden
Eray , Aleyna
Erkek Özhan , Serap
Hormone replacement (HR) therapy with estrogen (E2) alone or in combination with progesterone is used by women to compansate for the lack of these hormones during menopause. Despite the fact that HR has beneficial effects, long-term menopausal HR use has been associated with a higher risk of breast cancer. Drospirenone (Drsp), a fourth generation progestin derived from Spironolactone, is used together with estrogen (E2) and provides symptomatic relief in menopause. Drsp is also known to antagonize the Mineralocorticoid Receptor (MR) for which Aldosterone (Aldo) is a ligand modulating blood pressure. However, high throughput molecular comparisons between Drsp:E2 and other Progestin:E2 treatments in breast cancer cells are lacking. With the emerging NGS technology including RNA-seq, Chip-seq, and Hi-C, there are many datasets available on HR therapy in breast cancer cell lines to compare with each other; hence we first developed an R Shiny based web-tool called HRonBC where we collated such datasets. HRonBC, which is able to compare up to four HR-focused, two-group RNAseq datasets simultaneously, performs functional analysis for the selected gene sets through annotation by different terms as well as ChIP-Seq and/or Hi-C data. Accordingly, coverage and peak information of the selected genes from RNAseq data are displayed from the user-selected ChIP-Seq data while the Hi-C derived contact matrix of the relevant chromosome regions can be visualized. We also integrated into HRonBC the data from RNAseq and ChIP-seq experiments performed in our labs using breast cancer cells when exposed to different combinations of Drsp, E2, and/or Aldo.HRonBC has enabled us to seamlessly compare our data against other existing HR datasets in literature.


Biomechanical and histological outcome of combined raloxifene-estrogen therapy on skeletal and reproductive tissues
Tasci, Arzu; BİLGİLİ, HASAN; Altunay, Hikmet; Gecit, Mehmet Rusen; Keskin, Dilek (Elsevier BV, 2010-02-10)
Estrogen replacement is a potent therapy for postmenopausal osteoporosis. However, its carcinogenic effects on breasts and the uterus limit its utilization. Raloxifene has estrogen-like effects on bones without the carcinogenic symptoms on breast or uterine tissue. Their individual effects are well characterized, but the results of their interaction remains elusive. In this work, we investigate the consequences of a combined raloxifene/estrogen therapy on bone and uterus with experimental osteoporosis. 40 W...
Health-related quality of life of women with endometriosis: An Attachment-Diathesis Model of Chronic Pain perspective
Güvenç, İrem Berna; Bozo Özen, Özlem (2023-01-01)
Endometriosis is a common gynecological disorder that occurs in women of reproductive age, and negatively affects women’s quality of life. We tested ‘Attachment-Diathesis Model of Chronic Pain’ in a sample of Turkish women with endometriosis by analyzing the paths among attachment styles, pain catastrophizing, coping strategies, and health-related quality of life (HRQoL). Attachment anxiety was related to using less problem-focused coping and seeking more social support, while attachment avoidance was assoc...
GER, M; KARAMETE, BK; BEKSAC, MS; AKSEL, S (Elsevier BV, 1993-03-01)
Objective: To develop a probabilistic computer model to predict the preovulatory days of the menstrual cycle by given hormonal parameters such as follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone (P).
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity
Simoes, Bruno M.; et. al. (2015-09-01)
Breast cancers (BCs) typically express estrogen receptors (ERs) but frequently exhibit de novo or acquired resistance to hormonal therapies. Here, we show that short-term treatment with the anti-estrogens tamoxifen or fulvestrant decrease cell proliferation but increase BC stem cell (BCSC) activity through JAG1-NOTCH4 receptor activation both in patient-derived samples and xenograft (PDX) tumors. In support of this mechanism, we demonstrate that high ALDH1 predicts resistance in women treated with tamoxifen...
Computerized hybrid decision-making system for hormone replacement therapy in menopausal women
Bacak, Hikmet Özge; Leblebicioğlu, Mehmet Kemal; TANAÇAN, ATAKAN; BEKSAÇ, MEHMET SİNAN (IOS Press, 2019-01-01)
BACKGROUND: The diversity of the results of different hormone replacement therapy (HRT) protocols and the fuzziness of the conclusions have caused problems in routine clinical practice.
Citation Formats
M. Vural Özdeniz et al., “HRonBC: a web-tool tailored for analysis of transcriptomics and nucleome data for Hormone Replacement on Breast Cancer,” Erdemli, Mersin, TÜRKİYE, 2022, p. 3065, Accessed: 00, 2023. [Online]. Available: